AstraZeneca, Merck Drug Approved for Painful Childhood Ailment

Published April 13, 2020

AstraZeneca Plc and Merck & Co. received U.S. approval for a drug to treat a painful, damaging condition that afflicts children with a rare nerve-cell cancer.

Related Stories